Tech Company Financing Transactions
Carmot Therapeutics Funding Round
On 10/2/2020, Carmot Therapeutics raised $47 million in Series C investment from Amgen Ventures, Horizons Ventures and The Column Group.
Transaction Overview
Company Name
Announced On
10/2/2020
Transaction Type
Venture Equity
Amount
$47,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds to initiate early in 2021 a 26-week dose ranging phase 2 study for CT-868 and phase 1-2 studies for CT-388 and involve more than 300 patients.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
740 Heinz Ave.
Berkeley, CA 94710
USA
Berkeley, CA 94710
USA
Phone
Website
Email Address
Overview
Carmot Therapeutics develops drugs to treat inflammatory, metabolic and neurological diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stig Hansen
Chief Medical Officer
Allan Gordon
VP - Bus. Development
James Watson
Browse more venture capital transactions:
Prev: 10/2/2020: Pacaso venture capital transaction
Next: 10/2/2020: Yotta Savings venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs